Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Wet AMD”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT04993352
What this trial is testing

Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMD

Who this might be right for
Age Related Macular Degeneration
Shanghai Henlius Biotech 20
Early research (Phase 1)WithdrawnNCT00538538
What this trial is testing

Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD)

Who this might be right for
Retinal HemorrhageMacular Degeneration
Corewell Health East
Testing effectiveness (Phase 2)Looking for participantsNCT07587515
What this trial is testing

Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration

Who this might be right for
Neovascular (Wet) Age-Related Macular Degeneration
Eyconis INC. 30
Testing effectiveness (Phase 2)UnknownNCT06183814
What this trial is testing

EXG102-031 in Participants With wAMD

Who this might be right for
Neovascular Age-related Macular Degeneration
Guangzhou Jiayin Biotech Ltd 42
Not applicableStudy completedNCT03939767
What this trial is testing

Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease

Who this might be right for
Wet Age-related Macular Degeneration
Bayer 1,563
Early research (Phase 1)Study completedNCT01941082
What this trial is testing

RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration

Who this might be right for
Macular Degeneration
Hoffmann-La Roche 24
Early research (Phase 1)UnknownNCT01217762
What this trial is testing

Safety & Tolerability of the IRay System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

Who this might be right for
Age-Related Macular DegenerationWet Age-Related Macular DegenerationMacular Degeneration+2 more
Oraya Therapeutics, Inc. 62
Post-approval studies (Phase 4)Study completedNCT04679935
What this trial is testing

Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration

Who this might be right for
Age-related Macular Degeneration
Novartis Pharmaceuticals 52
Large-scale testing (Phase 3)Study completedNCT01482910
What this trial is testing

VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)

Who this might be right for
Macular Degeneration
Bayer 304
Not applicableUnknownNCT04640649
What this trial is testing

Prediction of Progression of Age-Related Macular Degeneration

Who this might be right for
Macular DegenerationMacular Degeneration, WetMacular Degeneration, Dry
University of Illinois at Chicago 278
Not applicableStudy completedNCT05082415
What this trial is testing

Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)

Who this might be right for
Age-related Macular Degeneration (AMD)
Novartis Pharmaceuticals 9,456
Early research (Phase 1)Ended earlyNCT03790852
What this trial is testing

Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO

Who this might be right for
Wet Age-related Macular DegenerationRetinal Vein OcclusionDiabetic Macular Edema
Kodiak Sciences Inc 121
Large-scale testing (Phase 3)Study completedNCT04270747
What this trial is testing

Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

Who this might be right for
Neovascular (Wet) Age-related Macular Degeneration (AMD)
Amgen 576
Testing effectiveness (Phase 2)Study completedNCT03558061
What this trial is testing

Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration

Who this might be right for
Wet Age-related Macular Degeneration
Alkahest, Inc. 30
Not applicableStudy completedNCT05131646
What this trial is testing

Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study

Who this might be right for
Neovascular Age-related Macular Degeneration
Clearside Biomedical, Inc. 15
Early research (Phase 1)Study completedNCT03777254
What this trial is testing

Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular Degeneration

Who this might be right for
Neovascular Age-related Macular Degeneration
RemeGen Co., Ltd. 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT05984927
What this trial is testing

NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration

Who this might be right for
Age-Related Macular Degeneration
Elisigen, Inc. 20
Large-scale testing (Phase 3)Active Not RecruitingNCT05112861
What this trial is testing

A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders

Who this might be right for
Age-Related Macular DegenerationNeovascular Age-related Macular DegenerationWet Macular Degeneration+2 more
Outlook Therapeutics, Inc. 120
Post-approval studies (Phase 4)Study completedNCT02257632
What this trial is testing

Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration

Who this might be right for
Wet Age-Related Macular Degeneration
Novartis Pharmaceuticals 41
Testing effectiveness (Phase 2)Ended earlyNCT01624636
What this trial is testing

Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 1
Next Page